ENDO 2025 at a glance
Get ready for ENDO 2025, where Endocrinology scientific insights and AI come together. This overview highlights the key presentations and cross-cutting AI-driven breakthroughs shaping tomorrow’s practice.
📅 Build your schedule around the topics that interest you. 📥 Download the ENDO 2025_Preview_by_LucidQuest
Dive deeper
Key Topics From ENDO 2025 Scientific Presentations
Pituitary Disease 🧠
-
Surveys show sleep disruption, anxiety, and fatigue are common after pituitary injury.
-
Early, specialized follow-up—especially in post-TBI and MEN1—improves QoL and hormone recovery.
Adrenal Disorders 🛡️
-
Crinecerfont (CRF1 antagonist) and Lu AG13909 (anti-ACTH mAb) cut androgen excess and lower steroid doses in congenital adrenal hyperplasia.
-
Obesity, smoking, and dysglycemia emerge as modifiable risks for adrenal adenomas.
Thyroid Health 🦋
-
Familial non-medullary thyroid cancer significantly worsens day-to-day wellbeing.
-
TgAb-positive differentiated thyroid cancer carries higher persistence/recurrence risk.
-
Plasma-exchange shows life-saving impact in thyroid storm.
Diabetes Care 🍏
-
CGM adoption in uninsured communities drives sharp A1c declines.
-
PCOS + impaired glucose tolerance heightens pre-eclampsia and lowers birthweight, underscoring early metabolic screening in pregnancy.
Bone & Oncology 🦴
-
Stopping denosumab nearly triples skeletal-event rates; post-bariatric denosumab preserves bone micro-architecture.
-
Post-thyroidectomy hypoparathyroidism raises renal and cardiac risks.
CardioMetabolic Risk ❤️
-
High LDL remains a major burden across Latin America.
-
CETP inhibitors and dual GLP-1/SGLT2 strategies improve lipids and liver fibrosis, but must be matched to local access gaps.
Rare Endocrine 📊
-
ΔBMD% at the hip is a strong fracture surrogate, potentially speeding osteoporosis drug trials.
-
Early switch from denosumab to zoledronic acid shows modest bone loss with no clinical fractures.
Artificial Intelligence and Machine Learning at ENDO 2025
AI in pituitary care
- CatBoost predicts somatostatin-analog resistance in acromegaly (AUROC 0.90), guiding early therapy shifts.
AI in thyroid care
- Image-based models flag thyroid eye disease and post-cancer breast-risk with higher accuracy than traditional scoring.
AI in metabolic care
- Radar-based waist-to-hip sensors and serum-proteomic signatures forecast insulin-resistance responses; ML beats manual dosing in pediatric hyperthyroidism.
AI in NAFLD screening
Ultrasound + clinical-AI triage fast-tracks NASH diagnosis, easing specialty bottlenecks.
📅 Build your schedule around the topics that interest you.
📥 Download the ENDO 2025_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.